博雅生物(300294.SZ):收到中證監不予核准公司發行股份、可轉債購買資產申請的決定
格隆匯4月13日丨博雅生物(300294.SZ)公佈,公司於2020年4月11日收到中國證監會出具的《關於不予核准博雅生物製藥集團股份有限公司發行股份、可轉換公司債券購買資產申請的決定》(證監許可[2020]550號),主要內容如下:
中國證監會上市公司併購重組審核委員會(“併購重組委”)於2020年2月18日舉行2020年第4次併購重組委會議,依法對公司發行股份、可轉換公司債券購買資產方案進行了審核。
根據申請文件,併購重組委認為公司未充分披露標的資產報告期業績大幅增長的原因和合理性,未充分披露業績預測依據的合理性,不符合《上市公司重大資產重組管理辦法》第四十三條的規定。
併購重組委會議以投票方式對公司方案進行了表決,同意票數未達到3票,方案未獲通過。根據《公司法》、《證券法》、《上市公司重大資產重組管理辦法》等有關規定,依法對公司發行股份、可轉換公司債券購買資產申請作出不予核准的決定。
公司董事會將自收到此決定之日起10日內對是否修改或終止本次方案作出決議,同時按照有關規定及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.